Novavax Stock Is Rising. Revenue Beats Estimates.
Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from ...
Moderna Shares Fall on Report HHS Is Reviewing Bird Flu Vaccine Contract
Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services ...
Forbes Daily: Nvidia Shakes Off DeepSeek Concerns With Robust Earnings
In today’s Forbes Daily, Nvidia’s fourth quarter earnings, Trump freezes credit cards, a federal investment in eggs, FDA flu vaccine meeting canceled and more.
manilatimes29m
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
(NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2024 and highlighted recent ...